Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 212-222 , July 2001

Monitoring treatment for osteoporosis by using bone densitometry

  • Glen M. Blake

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Glen M. Blake, PhD, Department of Nuclear Medicine, Guy's Hospital, St. Thomas Street, London SE1 9RT, England.
    • ,
  • Ignac Fogelman

References 

  1. on behalf of the European Foundation for Osteoporosis and Bone Disease Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int. 1997;7:390–406
  2. Cooper C, Campion G, Melton LJ. Hip fractures in the elderly: A world-wide projection. Osteoporos Int. 1992;2:285–289
  3. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35
  4. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone. 1994;15:377–386
  5. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998;338:736–746
  6. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal oestrogen. Ann Intern Med. 1992;117:1–9
  7. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent fractures in elderly women. N Engl J Med. 1992;327:1637–1642
  8. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–1443
  9. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifine on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641–1647
  10. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83:396–402
  11. Cosman F, Lindsay R. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int. 1998;62:475–480
  12. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037
  13. Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325–328
  14. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059
  15. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res. 1998;13:1747–1754
  16. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomised trial. JAMA. 1999;281:2189–2197
  17. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet. 1997;350:550–555
  18. Baran DT, Faulkner KG, Genant HK, et al. Diagnosis and management of osteoporosis: Guidelines for the utilization of bone densitometry. Calcif Tissue Int. 1997;61:433–440
  19. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. In: WHO Technical Report Series 843. Geneva: World Health Organization; 1994;
  20. Blake GM, Fogelman I. Interpretation of bone densitometry studies. In: Semin Nucl Med. 27:1997;p. 248–260
  21. Stegman MR, Recker RR, Davies KM, et al. Fracture risk as determined by prospective and retrospective study designs. Osteoporos Int. 1992;2:290–297
  22. Seeley DG, Browner WS, Nevitt MC, et al. Which fractures are associated with low appendicular bone mass in elderly women?. Ann Intern Med. 1991;115:837–842
  23. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72–75
  24. Melton LJ, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227–1233
  25. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J. 1996;312:1254–1259
  26. Düppe H, Gärdsell P, Nilsson B, et al. A single bone density measurement can predict fractures over 25 years. Calcif Tissue Int. 1997;60:171–174
  27. Jergas M, Glüer C-C. Assessment of fracture risk by bone density measurements. In: Semin Nucl Med. 27:1997;p. 261–275
  28. National Osteoporosis Foundation . Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8(suppl 4):S7–S80
  29. Faulkner KG, VonStetton E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343–350
  30. Delmas PD. Do we need to change the WHO definition of osteoporosis?. Osteoporos Int. 2000;11:189–191
  31. Miller PD. Controversies in bone mineral density diagnostic classifications. Calcif Tissue Int. 2000;66:317–319
  32. Frost ML, Blake GM, Fogelman I. Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound?. Osteoporos Int. 2000;11:312–330
  33. Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet. 1996;348:511–514
  34. Bauer DC, Glüer C-C, Cauley JA, et al. Broadband ultrasonic attenuation predicts fractures strongly and independently of densitometry in older women. Arch Intern Med. 1997;157:629–634
  35. Pluijm SMF, Graafmans WC, Bouter LM, et al. Ultrasound measurements for the prediction of osteoporotic fractures in elderly people. Osteoporos Int. 1999;9:550–556
  36. McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis: A double-blind, randomized, controlled trial. Ann Intern Med. 1998;128:253–261
  37. Hoskings D, Chilvers CE, Christiansen C, et al. Prevention of bone loss in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. N Engl J Med. 1998;338:485–492
  38. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  39. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: Results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082
  40. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645
  41. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–1352
  42. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91
  43. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray slamon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med. 2000;109:267–276
  44. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med. 2001;344:333–340
  45. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. JAMA. 2000;283:1318–1321
  46. Glüer C-C, Blake G, Lu Y, et al. Accurate assessment of precision errors: How to assess the reproducibility of bone densitometry techniques. Osteoporos Int. 1995;5:262–270
  47. Svendsen OL, Hassager C, Skodt V, et al. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine hip, and forearm: A human cadaver study. J Bone Miner Res. 1995;10:868–873
  48. Patel R, Blake GM, Rymer J, et al. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int. 2000;11:68–75
  49. Lindsay R, Aitkin JM, Anderson JB, et al. Long-term prevention of postmenopausal osteoporosis by estrogen. Evidence for an increased bone mass after delayed onset of estrogen treatment. Lancet. 1976;1:1038–1041
  50. Christiansen C, Christensen MS, McNair P, et al. Prevention of early postmenopausal bone loss: Controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980;10:273–279
  51. Miller PD, Watts NB, Licata AA, et al. Cyclical editronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med. 1997;103:468–476
  52. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2000;85:3109–3115
  53. abstr Marcus R, Gaich GA, Satterwhite JH, et al. Effects of baseline BMD, age, and prevalent vertebral fractures on the response of osteoporotic patients to LY333334 [rhPTH(1–34)]. J Bone Miner Res. 2000;15(suppl 1):S194
  54. Blake GM, Herd RMJ, Patel R, et al. The effect of weight change on total body dual x-ray absorptiometry: Results from a clinical trial. Osteoporos Int. 2000;11:832–839
  55. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802–809
  56. Kleerekoper M, Peterson EL, Nelson DA, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporos Int. 1991;1:155–161
  57. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVOS study. Osteoporos Int. 1998;8:4–12
  58. abstr Cummings SR, Black DM, Vogt TM, et al. Changes in BMD substantially underestimate the anti-fracture effects of alendronate and other antiresorptive drugs. J Bone Miner Res. 1996;11(suppl 1):S102
  59. abstr Cummings SR, Black DM, Pearson JB, et al. How much of the reduction of vertebral fractures by alendronate is explained by increased spine BMD?. J Bone Miner Res. 1999;14(suppl 1):S159
  60. abstr Black DM, Pearson J, Harris F, et al. Predicting the effect of antiresorptive treatments on risk of vertebral fractures: A meta-analysis. J Bone Miner Res. 1999;14(suppl 1):S137
  61. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 1999;42:1246–1254
  62. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive drugs are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231–236
  63. Delmas PD. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?. Bone. 2000;27:1–3
  64. abstr Faulkner KG, McClung MR, Ravn P, et al. Monitoring skeletal response to therapy in early postmenopausal women: Which bone to measure?. J Bone Miner Res. 1996;11(suppl 1):S96
  65. Blake GM, Herd RJM, Fogelman I. A longitudinal study of supine lateral DXA of the lumbar spine: A comparison with posteroanterior spine, hip and total body DXA. Osteoporos Int. 1996;6:462–470
  66. Faulkner KG. Bone densitometry: Choosing the proper skeletal site to measure. J Clin Densitom. 1998;1:279–285
  67. abstr Cummings SR, Palermo L, Ensrud KE, et al. Are nonresponders responding?. J Bone Miner Res. 2000;15(suppl 1):S144
  68. Ahmed AH, Ryan PJ, Snelling T, et al. Long-term compliance with hormone replacement treatment following screening for postmenopausal osteoporosis by bone density measurement. J Obstet Gynecol. 1996;16:41–44

PII: S0001-2998(01)80021-0

doi: 10.1053/snuc.2001.23528

Seminars in Nuclear Medicine
Volume 31, Issue 3 , Pages 212-222 , July 2001

Article Tools